NCT01924949View on ClinicalTrials.gov

Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection

PHASE2CompletedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

August 31, 2014

Conditions

Hepatitis C

Interventions

DRUG

LDV/SOF

Ledipasvir (LDV)/sofosbuvir (SOF) 90/400 mg FDC tablet administered orally once daily

Trial Locations (1)

Unknown

Boston

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY

NCT01924949 - Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection | Biotech Hunter | Biotech Hunter